COVID-19特定抗ウイルス薬の世界市場レポート2025年

COVID-19特定抗ウイルス薬の市場規模は、今後数年間で急成長が見込まれます。2029年にはCAGR16.9%で284億3,000万米ドルに成長します。予測期間における主な促進要因としては、パンデミックへの備えの重視、臨床試験活動の拡大、効果的な治療オプションに対するニーズの高まり、COVID-19亜種の流通量の増加、経口投与抗ウイルス薬の受容率の上昇などが挙げられます。市場を形成すると予想される注目すべき動向には、広域抗ウイルスソリューションの開発、医薬品開発におけるAI技術の活用、個別化抗ウイルス治療法の進歩、併用療法の革新、ウイルス変異対策へのゲノム洞察の応用などがあります。

COVID-19症例の増加は、今後COVID-19市場の特定抗ウイルス薬の成長を促進すると予想されます。COVID-19症例とは、COVID-19の原因となるSARS-CoV-2ウイルスが陽性と判定された患者を指します。症例数の増加は、より容易に拡散し、ワクチンや過去の感染による免疫を部分的に回避できる新型の出現によるものです。COVID-19特定抗ウイルス薬は、重症度と罹病期間の短縮に役立ち、患者の転帰を改善し、COVID-19患者の全体的な負担を軽減します。例えば、米国を拠点とする政府機関である疾病対策予防センターによると、2023年5月、追加的な死因を含むCOVID-19による死亡の平均では、2021年の4.2に対し、2022年には4.5の寄与疾患が挙げられています。したがって、COVID-19症例の増加は、COVID-19市場向けの特定抗ウイルス薬の成長を促進します。

COVID-19特定抗ウイルス薬市場で事業を展開する主要企業は、治療へのアクセス性と有効性を高めるため、経口抗ウイルス薬などの革新的な治療法の開発に注力しています。経口抗ウイルス療法は、COVID-19のようなウイルスの複製を阻害するために口から服用する薬であり、便利で効果的な治療オプションを提供します。例えば、2022年1月、インドを拠点とする製薬会社ルピン・リミテッドは、COVID-19の高リスク成人患者を治療するための抗ウイルス薬モルヌピラビルをモルヌループという商品名で発売しました。この内服薬は、重症化するリスクのある軽度から中等度のCOVID-19の成人を対象としています。MolnupiravirはSARS-CoV-2ウイルスの複製を阻害することにより、ウイルス量を低下させ、疾患の重症度を軽減します。症状発現後5日以内に投与を開始するのが最も効果的で、肥満、高齢、糖尿病、心血管疾患などの合併症を持つ患者には特に有効です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のCOVID-19特定抗ウイルス薬：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のCOVID-19特定抗ウイルス薬市場：成長率分析
• 世界のCOVID-19特定抗ウイルス薬市場の実績：規模と成長, 2019-2024
• 世界のCOVID-19特定抗ウイルス薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界のCOVID-19特定抗ウイルス薬：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のCOVID-19特定抗ウイルス薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 錠剤
• 注射
• 世界のCOVID-19特定抗ウイルス薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 入院患者
• 非入院患者
• 予防治療
• 世界のCOVID-19特定抗ウイルス薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヌクレオシド類似体
• プロテアーゼ阻害剤
• リボ核酸ポリメラーゼ阻害剤
• 侵入阻害剤
• モノクローナル抗体
• 世界のCOVID-19特定抗ウイルス薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 静脈内
• 皮下
• 吸入
• 世界のCOVID-19特定抗ウイルス薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界のCOVID-19特定抗ウイルス薬市場、錠剤、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口抗ウイルス錠
• 複合抗ウイルス錠
• 徐放錠
• 世界のCOVID-19特定抗ウイルス薬市場、注射、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内（IV）抗ウイルス注射
• 筋肉内（IM）抗ウイルス注射
• 皮下抗ウイルス注射

第7章 地域別・国別分析

• 世界のCOVID-19特定抗ウイルス薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のCOVID-19特定抗ウイルス薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• COVID-19特定抗ウイルス薬市場：競合情勢
• COVID-19特定抗ウイルス薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GSK plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Regeneron Pharmaceuticals Inc
• Hetero Drugs Limited
• Sun Pharmaceutical Industries Limited
• Shionogi and Co. Ltd.
• Cipla Limited
• Beximco Pharmaceuticals Limited
• BioCryst Pharmaceuticals Inc.
• Atea Pharmaceuticals Inc.
• Enanta Pharmaceuticals Inc.
• RedHill Biopharma Ltd.
• Aligos Therapeutics Inc.
• Synairgen plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• COVID-19特定抗ウイルス薬市場2029：新たな機会を提供する国
• COVID-19特定抗ウイルス薬市場2029：新たな機会を提供するセグメント
• COVID-19特定抗ウイルス薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Specific antiviral drugs for COVID-19 are therapeutics specifically developed to target and disrupt the replication or activity of the SARS-CoV-2 virus, the causative agent of COVID-19. These medications function by interfering with vital viral processes such as entry into host cells, replication, or assembly, thereby helping to lessen the severity and duration of the illness.

These antiviral drugs are available in both tablet and injectable formulations. Tablets are compressed solid dosage forms containing a fixed amount of active pharmaceutical ingredients along with excipients, typically in a flat or oval shape. These medications are prescribed for use in hospitalized patients, individuals receiving outpatient care, as well as for preventive purposes. They fall into various pharmacological categories, including nucleoside analogues, protease inhibitors, RNA polymerase inhibitors, entry inhibitors, and monoclonal antibodies, and are administered via oral, intravenous, subcutaneous, or inhalation routes. The distribution channels for these drugs include hospital pharmacies, retail pharmacies, and other pharmaceutical outlets.

The specific antiviral drugs for COVID-19 market size has grown rapidly in recent years. It will grow from $13.00 billion in 2024 to $15.23 billion in 2025 at a compound annual growth rate (CAGR) of 17.1%. Growth during the historic period was driven by factors such as the surge in hospital admissions due to severe infections, increased governmental investment in antiviral development, rising demand for targeted treatment solutions over generic alternatives, heightened awareness of the benefits of early antiviral administration, and enhanced collaboration among pharmaceutical firms.

The specific antiviral drugs for COVID-19 market size is expected to see rapid growth in the next few years. It will grow to $28.43 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. Key drivers in the forecast period include greater emphasis on pandemic preparedness, expansion of clinical trial activities, heightened need for effective treatment options, increasing circulation of COVID-19 variants, and rising acceptance of orally administered antiviral medications. Notable trends expected to shape the market include the development of broad-spectrum antiviral solutions, use of AI technologies in drug development, progress in personalized antiviral treatment methods, innovations in combination therapies, and the application of genomic insights to counter viral mutations.

The rising number of COVID-19 cases is expected to propel the growth of the specific antiviral drugs for the COVID-19 market going forward. COVID-19 cases refer to individuals who tested positive for the SARS-CoV-2 virus, which causes COVID-19. The increase in cases is due to the emergence of new variants that spread more easily and can partially evade immunity from vaccines or past infections. Specific antiviral drugs for COVID-19 help reduce the severity and duration of the illness, improving patient outcomes and lowering the overall burden of COVID-19 cases. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, on average, COVID-19 deaths that included additional causes of death had 4.5 contributing conditions listed in 2022, compared to 4.2 in 2021. Therefore, the rising number of COVID-19 cases drives the growth of the specific antiviral drugs for the COVID-19 market.

Major companies operating in the specific antiviral drugs for the COVID-19 market are focusing on developing innovative therapies, such as oral antiviral therapies, to enhance treatment accessibility and effectiveness. Oral antiviral therapies are medications taken by mouth to inhibit the replication of viruses like COVID-19, offering a convenient and effective treatment option. For instance, in January 2022, Lupin Limited, an India-based pharmaceutical company, launched the antiviral drug Molnupiravir under the brand name Molnulup to treat high-risk adult patients with COVID-19. This oral medication is intended for adults with mild to moderate COVID-19 who are at risk of developing severe illness. Molnupiravir works by inhibiting the replication of the SARS-CoV-2 virus, thereby helping to lower the viral load and reduce the severity of the disease. It is most effective when started within five days of symptom onset and is especially beneficial for individuals with comorbid conditions such as obesity, advanced age, diabetes, or cardiovascular disease.

In July 2024, GSK plc, a UK-based pharmaceutical company, collaborated with CureVac to develop and commercialize next-generation mRNA vaccines for COVID-19 and influenza. This collaboration aims to develop and commercialize innovative mRNA vaccines for influenza and COVID-19 to improve global public health outcomes. CureVac N.V. is a Germany-based company that develops therapies based on messenger RNA (mRNA) technology.

Major players in the specific antiviral drugs for covid 19 market are Pfizer Inc., Johnson and Johnson, Roche Holding AG, Merck And Co. Inc., Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Limited, Beximco Pharmaceuticals Limited, BioCryst Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Aligos Therapeutics Inc., Synairgen plc

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in specific antiviral drugs for COVID-19 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the specific antiviral drugs for COVID-19 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The specific antiviral drugs for COVID-19 market consists of sales of host-directed antivirals, immunomodulators, fusion inhibitors, helicase inhibitors, and tmprss2 inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Specific Antiviral Drugs For COVID 19 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on specific antiviral drugs for covid 19 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for specific antiviral drugs for covid 19 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The specific antiviral drugs for covid 19 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Tablet; Injection
• 2) By Indication: Hospitalized Patients; Non-Hospitalized Patients; Preventive Treatment
• 3) By Drug Class: Nucleoside Analogues; Protease Inhibitors; Ribonucleic Acid Polymerase Inhibitors; Entry Inhibitors; Monoclonal Antibodies
• 4) By Route Of Administration: Oral; Intravenous; Subcutaneous; Inhalation
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels

Subsegments

• 1) By Tablet: Oral Antiviral Tablets; Combination Antiviral Tablets; Extended-Release Tablets
• 2) By Injection: Intravenous (IV) Antiviral Injections; Intramuscular (IM) Antiviral Injections; Subcutaneous Antiviral Injections
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; Roche Holding AG; Merck And Co. Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Specific Antiviral Drugs For COVID 19 Market Characteristics

3. Specific Antiviral Drugs For COVID 19 Market Trends And Strategies

4. Specific Antiviral Drugs For COVID 19 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Specific Antiviral Drugs For COVID 19 Growth Analysis And Strategic Analysis Framework

• 5.1. Global Specific Antiviral Drugs For COVID 19 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Specific Antiviral Drugs For COVID 19 Market Growth Rate Analysis
• 5.4. Global Specific Antiviral Drugs For COVID 19 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Specific Antiviral Drugs For COVID 19 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Specific Antiviral Drugs For COVID 19 Total Addressable Market (TAM)

6. Specific Antiviral Drugs For COVID 19 Market Segmentation

• 6.1. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablet
• Injection
• 6.2. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitalized Patients
• Non-Hospitalized Patients
• Preventive Treatment
• 6.3. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nucleoside Analogues
• Protease Inhibitors
• Ribonucleic Acid Polymerase Inhibitors
• Entry Inhibitors
• Monoclonal Antibodies
• 6.4. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• Inhalation
• 6.5. Global Specific Antiviral Drugs For COVID 19 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.6. Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Antiviral Tablets
• Combination Antiviral Tablets
• Extended-Release Tablets
• 6.7. Global Specific Antiviral Drugs For COVID 19 Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Antiviral Injections
• Intramuscular (IM) Antiviral Injections
• Subcutaneous Antiviral Injections

7. Specific Antiviral Drugs For COVID 19 Market Regional And Country Analysis

• 7.1. Global Specific Antiviral Drugs For COVID 19 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Specific Antiviral Drugs For COVID 19 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market

• 8.1. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Specific Antiviral Drugs For COVID 19 Market

• 9.1. China Specific Antiviral Drugs For COVID 19 Market Overview
• 9.2. China Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Specific Antiviral Drugs For COVID 19 Market

• 10.1. India Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Specific Antiviral Drugs For COVID 19 Market

• 11.1. Japan Specific Antiviral Drugs For COVID 19 Market Overview
• 11.2. Japan Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Specific Antiviral Drugs For COVID 19 Market

• 12.1. Australia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Specific Antiviral Drugs For COVID 19 Market

• 13.1. Indonesia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Specific Antiviral Drugs For COVID 19 Market

• 14.1. South Korea Specific Antiviral Drugs For COVID 19 Market Overview
• 14.2. South Korea Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Specific Antiviral Drugs For COVID 19 Market

• 15.1. Western Europe Specific Antiviral Drugs For COVID 19 Market Overview
• 15.2. Western Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Specific Antiviral Drugs For COVID 19 Market

• 16.1. UK Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Specific Antiviral Drugs For COVID 19 Market

• 17.1. Germany Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Specific Antiviral Drugs For COVID 19 Market

• 18.1. France Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Specific Antiviral Drugs For COVID 19 Market

• 19.1. Italy Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Specific Antiviral Drugs For COVID 19 Market

• 20.1. Spain Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Specific Antiviral Drugs For COVID 19 Market

• 21.1. Eastern Europe Specific Antiviral Drugs For COVID 19 Market Overview
• 21.2. Eastern Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Specific Antiviral Drugs For COVID 19 Market

• 22.1. Russia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Specific Antiviral Drugs For COVID 19 Market

• 23.1. North America Specific Antiviral Drugs For COVID 19 Market Overview
• 23.2. North America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Specific Antiviral Drugs For COVID 19 Market

• 24.1. USA Specific Antiviral Drugs For COVID 19 Market Overview
• 24.2. USA Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Specific Antiviral Drugs For COVID 19 Market

• 25.1. Canada Specific Antiviral Drugs For COVID 19 Market Overview
• 25.2. Canada Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Specific Antiviral Drugs For COVID 19 Market

• 26.1. South America Specific Antiviral Drugs For COVID 19 Market Overview
• 26.2. South America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Specific Antiviral Drugs For COVID 19 Market

• 27.1. Brazil Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Specific Antiviral Drugs For COVID 19 Market

• 28.1. Middle East Specific Antiviral Drugs For COVID 19 Market Overview
• 28.2. Middle East Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Specific Antiviral Drugs For COVID 19 Market

• 29.1. Africa Specific Antiviral Drugs For COVID 19 Market Overview
• 29.2. Africa Specific Antiviral Drugs For COVID 19 Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Specific Antiviral Drugs For COVID 19 Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Specific Antiviral Drugs For COVID 19 Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Specific Antiviral Drugs For COVID 19 Market Competitive Landscape And Company Profiles

• 30.1. Specific Antiviral Drugs For COVID 19 Market Competitive Landscape
• 30.2. Specific Antiviral Drugs For COVID 19 Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Specific Antiviral Drugs For COVID 19 Market Other Major And Innovative Companies

• 31.1. GSK plc
• 31.2. Eli Lilly and Company
• 31.3. Gilead Sciences Inc.
• 31.4. Regeneron Pharmaceuticals Inc
• 31.5. Hetero Drugs Limited
• 31.6. Sun Pharmaceutical Industries Limited
• 31.7. Shionogi and Co. Ltd.
• 31.8. Cipla Limited
• 31.9. Beximco Pharmaceuticals Limited
• 31.10. BioCryst Pharmaceuticals Inc.
• 31.11. Atea Pharmaceuticals Inc.
• 31.12. Enanta Pharmaceuticals Inc.
• 31.13. RedHill Biopharma Ltd.
• 31.14. Aligos Therapeutics Inc.
• 31.15. Synairgen plc

32. Global Specific Antiviral Drugs For COVID 19 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Specific Antiviral Drugs For COVID 19 Market

34. Recent Developments In The Specific Antiviral Drugs For COVID 19 Market

35. Specific Antiviral Drugs For COVID 19 Market High Potential Countries, Segments and Strategies

• 35.1 Specific Antiviral Drugs For COVID 19 Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Specific Antiviral Drugs For COVID 19 Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Specific Antiviral Drugs For COVID 19 Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer